| Outcome Measures: |
Primary: Determine if INZ-701 increases PPi levels, For each participant, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time to determine if there's been a change., 26 days (Treatment Period) | Secondary: Assess the Time to Maximum Serum Concentration (Tmax), For each participant, the maximum concentration of INZ-701 in the serum will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time., 26 days (Treatment Period)|Assess the Maximum Serum Concentration (Cmax) of INZ-701, For each participant, the maximum concentration of INZ-701 in the serum will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time., 26 days (Treatment Period)|Assess the Area under the concentration-time curve over the dosing interval (AUCtau), For each participant, variation of concentration of INZ-701 in the serum will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time., 26 days (Treatment Period)|Assess the Clearance after extravascular administration of drug (CL/F), For each participant, clearance of INZ-701 from the body will be measured via a series of blood samples obtained throughout the study, comparing the participant's baseline value over time., 26 days (Treatment Period)|Assess ENPP1 Activity, For each participant, ENPP1 activity is a measurement of INZ-701 activity in human serum using a chromogenic based method., 26 days (Treatment Period)
|
| Locations: |
South Florida Nephrology Research, Coral Springs, Florida, 33071, United States|Elixia Health, Hollywood, Florida, 33024, United States
|
